News
-
-
PRESS RELEASE
Zentek and Triera Biosciences Ltd. Achieve Positive Results Against Avian Influenza (H5N1) using Multivalent Aptamer Technology
Zentek Ltd.'s subsidiary, Triera Biosciences, prioritizes developing prophylaxis & therapeutics for avian influenza H5N1 outbreak. Aptamer technology aims to neutralize virus, with promising results & potential for pandemic prevention -
-
-
-
-
-
PRESS RELEASE
Zentek Announces Promising Preclinical Safety and Toxicity Results achieved by Triera Biosciences Ltd. for C19HBA
Zentek Ltd. announces successful safety and toxicity testing of C19HBA SARS-CoV-2 universal aptamer in preclinical trials, showing promising results for future human therapeutics -
PRESS RELEASE
Zentek Announces Positive Therapeutic Results achieved by Triera Biosciences for C19HBA
Zentek Ltd.'s subsidiary Triera Biosciences completes successful testing of C19HBA aptamer as therapeutic for SARS-CoV-2, outperforming monoclonal antibody in preclinical trials. C19HBA shows potential for prophylaxis and treatment. Future clinical trials and partnerships to be pursued -
PRESS RELEASE
Zentek Completes Study Quantifying Energy and Emission Savings of ZenGUARD(TM)-Enhanced HVAC Filters
Zentek Ltd. announces the completion of a new study showing significant energy and cost savings for commercial buildings adopting ZenGUARDTM Enhanced Air Filters. The study highlights the reduction of infection risk and the potential to reduce HVAC energy consumption and CO2 emissions. Find out more on Zentek's website.